How ADCs Act as a “Trojan Horse Effect” to Target & Attack Cancer Cells,
an Industry Supported Symposium
Activity Overview
The GOG Foundation, Inc., GOG Partners and WAGO welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to view the How ADCs Act as a “Trojan Horse Effect” to Target & Attack Cancer Cells Industry Supported Symposium Enduring Educational Materials that were presented during the WAGO 2023 Annual Meeting.
The GOG Foundation, Inc. and WAGO are grateful for its commercial supporter for their unrestricted educational grant associated with this Symposium: Immunogen
Target Audience
The target audience for this activity is community and academic gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other providers who treat patients with gynecologic malignancies.Learning Objectives
Upon completion of the activities in this series, learners will demonstrate:- Identify how to utilize biomarkers effectively in ovarian cancer to target cancer cells and maintain healthy tissue.
- Understand past, present, and future trials integrating ADCs and other novel therapies in ovarian cancer treatments.
- Educate on best strategies to mitigate adverse reactions.
Faculty
- Kathleen Moore, MD, Stephenson Cancer Center, University of Oklahoma
- Bradley Monk, MD, University Cancer Associates, Inc.
- Thomas Herzog, MD, University of Cincinnati
Agenda & Presentation Materials
How ADCs Act as a “Trojan Horse Effect” to Target & Attack Cancer Cells, an Industry Supported Symposium at the WAGO 2023 Annual MeetingPresented on Friday, June 16, 2023 | 11:40 am – 1:10 pm PST
Enduring Educational Materials will be available on demand for six months following the live presentation.
View Recording11:40 am – 11:45 am
Welcome & Introduction
Kathleen Moore, MD, Stephenson Cancer Center, Oklahoma City, Oklahoma, USA
Kathleen Moore, MD, Stephenson Cancer Center, Oklahoma City, Oklahoma, USA
11:45 am – 12:00 pm
Biomarker Testing in Ovarian Cancer – View Presentation
Bradley Monk, MD, University Cancer Associates, Inc.
Bradley Monk, MD, University Cancer Associates, Inc.
12:00 pm – 12:10 pm
Discussion (Testing and when to test, challenges in development)
All Faculty
All Faculty
12:10 pm – 12:25 pm
ADCs in Ovarian Cancer – View Presentation
Thomas Herzog, MD, University of Cincinnati
Thomas Herzog, MD, University of Cincinnati
12:25 pm – 12:35 pm
Discussion
All Faculty
All Faculty
12:35 pm – 12:50 pm
The Trojan Horse Effect, best approach and strategies with ADCs – View Presentation
Kathleen Moore, MD, Stephenson Cancer Center, Oklahoma City, Oklahoma, USA
Kathleen Moore, MD, Stephenson Cancer Center, Oklahoma City, Oklahoma, USA
12:50 pm – 1:10 pm
Panel Discussion: Other Adverse with ADCs
All Faculty